Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"RNA, U6 small nuclear 340, pseudogene" (RNU6-340P) is a **pseudogene derived from the U6 small nuclear RNA (snRNA)** gene family. U6 snRNA is an essential, highly conserved noncoding RNA component of the spliceosome, the major nuclear complex responsible for excising introns during pre-mRNA splicing in eukaryotes[3][1]. However, as a **pseudogene**, RNU6-340P is a **non-functional, duplicated genomic copy** of the parental U6 gene that has lost the ability to code for a functional RNA molecule due to accumulated mutations or truncations[2][5]. Such snRNA pseudogenes are common in vertebrate genomes, often generated by **retrotransposition mechanisms** (such as LINE-1-mediated events) and reflect the evolutionary mobility of small nuclear RNA genes[2]. Pseudogenes like RNU6-340P are not known to act as enzymes, receptors, or active molecular targets, nor are they directly involved in disease processes or targeted by drugs[2][3]. **Key points:** - This entry is a **pseudogene**, not an active gene or molecular target. - It does not encode a protein, enzyme, receptor, or regulatory RNA product[2][3][5]. - No known biological functions, disease roles, or drug interactions are associated with this pseudogene. - Its nomenclature "340" refers to its annotation as the 340th U6 pseudogene in the human genome. **Notable issues:** - This is not a valid therapeutic target; it is a **non-functional genomic element**. - Entries for functional spliceosome-related U6 snRNA should instead refer to the canonical "U6 small nuclear RNA" (RNU6-1 or RNU6), which is essential for splicing, but not this pseudogene[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 340, pseudogene (RNU6-340P).